Catalog No.
DHJ48703
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-lambda
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
SOST, Sclerostin
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9BQB4
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BPS-804, MOR-05813, CAS: 1847394-95-9
Clone ID
Setrusumab
Note
For research use only. Not suitable for clinical or therapeutic use.
BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial., PMID:28370407
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia., PMID:28436937
Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis., PMID:35264832
Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta., PMID:38472351
Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab-a sclerostin neutralizing antibody., PMID:38982734
Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study., PMID:39012717
Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGFB signalling in vitro and in an OIM mouse model., PMID:39185375
Non-invasive quantification of bone (re)modeling dynamics in adults with osteogenesis imperfecta treated with setrusumab using timelapse high-resolution peripheral-quantitative computed tomography., PMID:39849981
Clinical development of BPS804 for osteogenesis imperfecta: from failure to fruition?, PMID:39989232
Correction to: Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study., PMID:40037367
BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial, PMID: 28370407
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia, PMID: 28436937
For research use only. Not for human or drug use.
